Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul 1;29(3):187-189.
doi: 10.4078/jrd.2022.29.3.187.

A Case of Superficial Thrombo-occlusive Vascular Disease in a Patient With Rheumatoid Arthritis

Seong-Ji Park  1 , Chung-Il Joung  1 , Seung Hyun Cheong  2 , Han Young Ryu  3 , Ga Hyun Lee  2 , Gil Jae Pyo  2 , Mihye Kwon  1
Affiliations
Case Reports

A Case of Superficial Thrombo-occlusive Vascular Disease in a Patient With Rheumatoid Arthritis

Seong-Ji Park et al. J Rheum Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Her skin lesions with papules and ulcers were shown on her left leg unilaterally (A), and the biopsy site was marked (B). The crust formation (asterisks) was found in the epidermis layer, and there were diffuse infiltrates of inflammatory cells (black arrows) in the upper dermis (x100 high power field [HPF]) (C). High magnification showed neutrophils, lymphocytes (black arrowhead) in the upper dermis, and thrombosis (green arrowheads) in capillaries, and red blood cell extravasation (yellow arrowheads) could be seen (x200 HPF) (D).
Fig. 2
Fig. 2
The changes of the skin lesions. The initial appearance of the skin lesion at her second visit for worsening in December 2020 (A) and after a biopsy, she had prescribed rivaroxaban for superficial thrombo-occlusive vascular disease. In 2 weeks, the skin lesion which being treated with rivaroxaban (B), and in 3 months, she had complete resolution of symptoms (C).
See this image and copyright information in PMC

References

    1. Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider SW, Gerss J, et al. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol. 2016;3:e72–9. doi: 10.1016/S2352-3026(15)00251-3. - DOI - PubMed
    1. Beyer-Westendorf J, Schellong SM, Gerlach H, Rabe E, Weitz JI, Jersemann K, et al. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017;4:e105–13. doi: 10.1016/S2352-3026(17)30014-5. - DOI - PubMed
    1. Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 2014;16:435. doi: 10.1186/s13075-014-0435-y. - DOI - PMC - PubMed
    1. Chung WS, Peng CL, Lin CL, Chang YJ, Chen YF, Chiang JY, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014;73:1774–80. doi: 10.1136/annrheumdis-2013-203380. - DOI - PubMed
    1. Hairston BR, Davis MD, Pittelkow MR, Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol. 2006;142:1413–8. doi: 10.1001/archderm.142.11.1413. - DOI - PubMed

Publication types

LinkOut - more resources